Integrated Platform for Measuring and Reducing Symptoms of Autism Spectrum Disorder

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age2-8
SponsorState University of New York - Upstate Medical University

About this trial

This study will consist of a randomized, double-blind, sham-controlled clinical trial at SUNY Upstate Medical University and Mt. Sinai Medical Center with 80 autistic children evaluating the effects of transcranial photobiomodulation (tPBM) on multiple clinically validated scales.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ages 2 - 8

Autism spectrum disorder diagnosis

CARS-2 score of 30 - 45

Disqualifiers

CARS scores less than 30 or over 45.

Taking psychotropic medications.

Having skin lesions on scalp

Having history of seizures

Trial design

Design model

Parallel

Treatments tested in this trial

  • Cognilum TM: Light Treatment Condition

    Device

    The children will wear the CognilumTM device for approximately 10 minutes at a time, twice a week, for a period of 10 weeks.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: CognilumTMExperimental treatment 1 intervention
Group B: Sham controlSham comparator 1 intervention

Trial outcomes

Primary outcomes

1

Childhood Autism Rating Scale, Second edition

Psychometrically sound measure for identifying children with autism and their symptom severity through quantifiable ratings based on direct observation. Raw scores may range from 15 to 60, which are then converted to T-scores. Higher scores indicate greater severity.

Time frame
10 weeks

Secondary outcomes

1

Social Responsiveness Scale, Second Edition

Psychometrically sound measure for identifying the presence and severity of social impairment within the autism spectrum and differentiates it from that which occurs in other disorders. Raw scores may range from 65 to 260, which are then converted to T-scores. Higher scores indicate greater severity.

Time frame
10 weeks
2

Clinical Global Impressions Scale

A well-established, brief assessment of the clinician's view of the patient's global functioning prior to and after initiating intervention. Ratings range from 1 (Normal) to 7 (Among the most severe).

Time frame
10 weeks

Other outcomes

1

Clinical Interviews

Caregiver interviews obtaining information on the participant's functioning.

Time frame
10 weeks
2

Aberrant Behavior Checklist

Behavior assessment

Time frame
10 weeks
3

Repetitive Behavior Scale

Assessment of restricted and repetetive behaviors

Time frame
10 weeks
4

Sensory Profile Caregiver Questionnaire -- Second Edition

Assessment of sensory needs

Time frame
10 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

State University of New York - Upstate Medical University

Lead sponsor

JelikaLite LLC

Collaborator

Mt. Sinai School of Medicine, New York, New York

Collaborator

MetroEHS

Collaborator